胡劲松, 蔡三军. The microRNA of advanced colorectal cancer predict efficacy of first-line chemotherapy[J]. China Oncology, 2013, 23(7): 499-504. DOI: 10.3969/j.issn.1007-3969.2013.07.004.
The microRNA of advanced colorectal cancer predict efficacy of first-line chemotherapy
Background and purpose: Colorectal cancer (CRC) is the most frequently occurring primary malignant tumor. Chemotherapy can reduce the risk of local and distant relapse. Therefore
it is very important to find new biomarkers that can predict chemoresistant and help in treatment decisions. Methods: In this study
we examined the expression levels of 1 200 human miRNAs in 6 CRC tissues
using miRNA profiling assay arrays. A validation study was done to corroborate a subset of the results
including expression levels of miR-4299
miR-196b
miR-324-5p
miR-455-3p and miR-939
by analyzing 100 specimens of stage Ⅳ colorectal adenocarcinoma (not respond and respond to the chemotherapy) to quantitative real-time PCR. We modeled the relationship between the expression levels of these miRNAs and the survival rate of 100 CRC patients by Kaplan-Meier method. Results: Expression profiles in CRCs suggested that 5 miRNAs were candidate markers associated with the chemoresistance of colorectal cancer. We found that miR-4299 and -196b had significant diagnostic value for chemoresistance CRC. miR-4299 yielded an AUC (the areas under the ROC curve) of 0.784 and miR-196b yielded an AUC of 0.647 in discriminating CRC from controls. Combined ROC analysis using these 2 miRNAs revealed an elevated AUC of 0.848 with 67.9% sensitivity and 90.9% specificity in discriminating chemoresistance CRC. The low level of miR-4299 expression and the high level of -196b expression are significantly correlated with the good survival of CRC patients. Conclusion: These data suggest that miR-4299 and -196b have strong potential as novel biomarkers for chemoresistant detection of colorectal cancer.
Chinese expert consensus on whole-process management of chemotherapy-related diarrhea (2025 edition)
Effectiveness and safety analysis of camrelizumab combined with chemotherapy and targeted therapy in patients with recurrent, metastatic, and treatment-naive advanced cervical cancer: a retrospective cohort study
A prospective single-arm study of the efficacy and safety of lobaplatin-based HIPEC combined with optimal support in the treatment of abdominal metastatic cancer
A retrospective study of pembrolizumab combined with XELOX regimen in the treatment of advanced gastric cancer
The progress of treatment for brain metastases of triple-negative breast cancer
Related Author
Association Committee of Rehabilitation and Palliative Care China Anti-Cancer
Association Committee of Cancer Pain Fujian Anti-Cancer
Sumei FAN
Congling XIN
Laifang ZHU
Chang LIU
Rui XU
Zhengrong ZHOU
Related Institution
Department of Surgical Oncology, Minhang Branch, Fudan University Shanghai Cancer Center
Department of Pharmacy, Minhang Branch, Fudan University Shanghai Cancer Center
Department of Diagnostic Radiology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University
Department of Diagnostic Radiology, Minhang Branch, Fudan University Shanghai Cancer Center
Department of Gynecological Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University